Analysts Offer Insights on Healthcare Companies: InflaRx NV (NASDAQ: IFRX) and Catalyst Biosciences Inc (NASDAQ: CBIO)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on InflaRx NV (NASDAQ:IFRX) and Catalyst Biosciences Inc (NASDAQ:CBIO).

InflaRx NV (IFRX)

In a report released yesterday, Madhu Kumar from B.Riley FBR reiterated a Buy rating on InflaRx NV, with a price target of $43. The company’s shares opened today at $30.62.

Kumar commented:

“This morning, InflaRx (IFRX) announced 2Q18 earnings and provided a corporate update. We reiterate our belief that lead asset, complement C5a monoclonal antibody (mAb) IFX-1, could transform the treatment of hidradenitis suppurativa (HS), with top-line data from ongoing Phase IIb studies potentially serving as a positive catalyst for IFRX shares. Beyond HS, we see additional upside potential for IFX-1 in ANCA-associated vasculitis (AAV), with Phase II studies expected to start shortly. After 2Q18 model updates, we reiterate our IFRX Buy rating and $43 price target.”

According to, Kumar is a 5-star analyst with an average return of 28.3% and a 54.0% success rate. Kumar covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Arbutus Biopharma Corporation, and Clementia Pharmaceuticals Inc.

InflaRx NV has an analyst consensus of Strong Buy, with a price target consensus of $45.80.

See today’s analyst top recommended stocks >>

Catalyst Biosciences Inc (CBIO)

B.Riley FBR analyst George Zavoico reiterated a Hold rating on Catalyst Biosciences Inc today and set a price target of $12.50. The company’s shares opened today at $10.15.

Zavoico wrote:

“At international medical conferences in Biosciences Inc. (CBIO) presented results of early stage clinical trials showing that its rationally engineered coagulation factors CB2679d/ISU304 (CB2679) and marzeptacog alfa (MarzAA) for the treatment of severe hemophilia B and hemophilia A or B with inhibitors, respectively, prevent spontaneous and acute bleeding events with daily subcutaneous dosing. However, two patients in a Phase I/ II trial of CB2679d/ISU304 generated neutralizing antibodies that inhibited the engineered coagulation factor. Catalyst Bio provided a corporate update along with its 2Q18 financial results last week on August 2 that outlined their strategy for continuing the clinical development of both product candidates.”

According to, Zavoico is a 4-star analyst with an average return of 7.5% and a 46.7% success rate. Zavoico covers the Healthcare sector, focusing on stocks such as Cellular Biomedicine Group, Actinium Pharmaceuticals, and Asterias Biotherapeutics.

Currently, the analyst consensus on Catalyst Biosciences Inc is a Moderate Buy with an average price target of $23.75.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *